Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Protein Supplementation to Enhance Exercise Capacity in COPD

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04027413
Recruitment Status : Completed
First Posted : July 22, 2019
Last Update Posted : October 8, 2020
Sponsor:
Collaborator:
Nutricia, Inc.
Information provided by (Responsible Party):
University College, London

Brief Summary:

Chronic obstructive pulmonary disease (COPD) is a common smoking-related lung disease.

Pulmonary Rehabilitation (PR) is a six-week supervised group exercise and education class. PR is an effective intervention in COPD to reduce symptoms, improve exercise performance and prevent exacerbation. Exercise intolerance/limitation is one of the commonest issues with COPD patients and this may be compounded by reduced muscle mass and malnutrition. COPD patients lose body weight and skeletal muscle mass which leads to muscle weakness and dysfunction, thus impacting functional ability and quality of life. Muscle weakness is caused by a prolonged sedentary lifestyle and voluntary immobilization. Importantly, being under-weight is associated with an increased risk of mortality in COPD.

Nutritional supplementation have been used to overcome malnutrition in COPD patients. It has been shown that nutritional support integrated with exercise training can improve exercise activity, decreased the risk of mortality, and improve muscle strength in undernourished COPD patients. However, uptake of nutritional supplementation during pulmonary rehabilitation, where the potential benefit may be greatest, has been limited by the absence of rigorous evidence-based studies supporting use.

Investigators want to investigate the effect of a nutritional supplement during a PR program on exercise capacity in COPD patients. Investigators will collect demographic data, distribute questionnaires, measure exercise performance, and some additional measurements.


Condition or disease Intervention/treatment Phase
COPD Dietary Supplement: fortisip compact protein Dietary Supplement: preOp Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 68 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Participants will be randomised using a web-based service called 'sealed envelope' and stratified BMI less and equal or more than 20 kg/m2 to control group or interventional group.
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:

Participant in both groups will received either the supplement or the placebo/ control products. Both products will be labelled the same way.

Investigator: someone not from the research team will run the randomisation and deliver the products to participants.

Outcome Assessor: will not be involved in the randomisation and will be blinded

Primary Purpose: Diagnostic
Official Title: A Double-Blind, Randomised, Placebo-Controlled Trial of Protein Supplementation to Enhance Exercise Capacity in Chronic Obstructive Pulmonary Disease
Actual Study Start Date : January 7, 2019
Actual Primary Completion Date : March 23, 2020
Actual Study Completion Date : October 2, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Placebo Comparator: Placebo/ Control
participants in this group will receive carbohydrate product which does not include protein at all
Dietary Supplement: preOp
(100% carbohydrate).

Experimental: Intervention group
Participants in this group will receive high protein product
Dietary Supplement: fortisip compact protein
(24% protein; 41% carbohydrate; 35% fat)




Primary Outcome Measures :
  1. Exercise capacity [ Time Frame: 12 weeks ]
    The difference in change of exercise capacity before and and after pulmonary rehabilitation between intervention and control groups measured by Incremental Shuttle Walk Test.


Secondary Outcome Measures :
  1. Peripheral muscle strength [ Time Frame: 12 weeks ]
    The difference in change of peripheral muscle strength Before and and after pulmonary rehabilitation between intervention and control groups measured by Hand Dynamometer.

  2. Rectus femoris muscle cross-sectional [ Time Frame: 12 weeks ]
    The difference in change of Rectus femoris muscle cross-sectional area before and and after pulmonary rehabilitation between intervention and control groups measured by portable ultrasound.

  3. Body composition [ Time Frame: 12 weeks ]
    The difference in change of body composition fat mass (FM) before and and after pulmonary rehabilitation between intervention and control groups measured by a device called Bodystat.

  4. Physical activity [ Time Frame: 14 days ]
    The difference in change of physical activity before and and after pulmonary rehabilitation between intervention and control groups measured by step-counter (YAMAX SW200).

  5. Health-related quality of life [ Time Frame: 12 weeks ]
    The difference in change of health-related quality before and after pulmonary rehabilitation between intervention and control groups measured by Hospital Anxiety and Depression Scale. consists of seven items for anxiety and seven items for depression, each item has a score from 0-3.This means that a person can score between 0 and 21 for either abnormal, respectively. 0-7 = Normal, 8-10 = Borderline abnormal and 11-21 = Abnormal

  6. Body circumferences [ Time Frame: 12 weeks ]
    The difference in change of waist circumference before and and after pulmonary rehabilitation between intervention and control groups measured by a tape.

  7. Body composition [ Time Frame: 12 weeks ]
    The difference in change of body composition fat free mass (FFM) before and and after pulmonary rehabilitation between intervention and control groups measured by a device called Bodystat.

  8. Body composition [ Time Frame: 12 weeks ]
    The difference in change of body composition fat free mass index (FFMI) before and and after pulmonary rehabilitation between intervention and control groups measured by a device called Bodystat.

  9. Body circumferences [ Time Frame: 12 weeks ]
    The difference in change of hip circumference before and and after pulmonary rehabilitation between intervention and control groups measured by a tape.

  10. Body circumferences [ Time Frame: 12 weeks ]
    The difference in change of mid-thigh circumference before and and after pulmonary rehabilitation between intervention and control groups measured by a tape.

  11. Health-related quality of life [ Time Frame: 12 weeks ]
    The difference in change of health-related quality before and after pulmonary rehabilitation between intervention and control groups measured by the COPD Assessment Test Questionnaire.

  12. Health-related quality of life [ Time Frame: 12 weeks ]
    The difference in change of health-related quality before and after pulmonary rehabilitation between intervention and control groups measured by St. George's Respiratory Questionnaire.

  13. intervention compliance [ Time Frame: 6 weeks ]
    participants intervention compliance will be assessed by sheet

  14. Food intake [ Time Frame: 12 weeks ]
    Food intake for 3 consecutive days before, during, and after PR by food diary

  15. Lower limb function [ Time Frame: 12 weeks ]
    The difference in change of lower limb function before and after pulmonary rehabilitation between intervention and control groups measured Sit to Stand - Five Test.

  16. Malnutrition risk [ Time Frame: 12 weeks ]
    The difference in change of Malnourished risk before and after pulmonary rehabilitation between intervention and control groups measured Malnutrition Universal Screening Tool .

  17. Disability associated with breathlessness [ Time Frame: 12 weeks ]
    The difference in change of Disability associated with breathlessness before and after pulmonary rehabilitation between intervention and control groups measured by Medical Research Council breathlessness scale .

  18. Body weight [ Time Frame: 12 weeks ]
    The difference in change of body weight before and after pulmonary rehabilitation between intervention and control groups measured by digital scales.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Confirmed COPD (post-bronchodilator forced vital capacity in one second: forced vital capacity ratio <0.7)
  2. >10 smoking pack year history.
  3. Enrolling on a pulmonary rehabilitation programme.
  4. Age of 18 and above.

Exclusion Criteria:

  1. Patients with any physical or mental health disorders preventing compliance with trial protocol.
  2. Unable to communicate in English
  3. Malabsorption syndrome
  4. Unable to perform the Incremental Shuttle Walk Test
  5. Patients already using other types of oral dietary supplement, under the care of a dietitian.
  6. Galactosaemia (contraindication)
  7. Known cow's milk protein allergy or lactose intolerance
  8. BMI >30kg/m2 without recent weight loss of >5%

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04027413


Locations
Layout table for location information
United Kingdom
Central and North West London Foundation Trust
London, United Kingdom, NW1 0PE
Sponsors and Collaborators
University College, London
Nutricia, Inc.
Layout table for additonal information
Responsible Party: University College, London
ClinicalTrials.gov Identifier: NCT04027413    
Other Study ID Numbers: 18/LO/1842
First Posted: July 22, 2019    Key Record Dates
Last Update Posted: October 8, 2020
Last Verified: October 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University College, London:
Pulmonary Rehabilitation
Nutrtional supplements